|Bid||0.00 x 800|
|Ask||24.33 x 900|
|Day's Range||22.15 - 23.13|
|52 Week Range||5.51 - 26.58|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||21.31|
|Earnings Date||Feb 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Feb 01, 2019|
|1y Target Est||26.67|
Meridian Bioscience (VIVO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.
Meridian Bioscience (VIVO) closed at $22.13 in the latest trading session, marking a +1.33% move from the prior day.